Dr. Siders received his B.Sc. Degree in 1990 from the University of North Carolina at Pembroke and his Ph.D.degree in 1995 from the Department of Microbiology and Immunology at Wake Forest University. He trained as a post-doctoral fellow at both the National Cancer Institute and at MethylGene in the area of gene therapy and cancer. He joined Genzyme in 1998 and was involved in evaluating several immunotherapy candidates in pre-clinical cancer models using both viral and non-viral platforms. Work during his tenure involved identifying and developing therapeutics for both cancer and autoimmune disease. Most recently, Dr. Siders became responsible for leading the Neuroimmunology Research Group focusing on the identification and validation of therapeutic targets for multiple sclerosis. He has been involved with several development programs including alemtuzumab where he participated in the FDA Advisory Committee meeting and regulatory filings. In July of 2017, Dr. Siders joined SHEPHERD Therapeutics as Chief Development Officer to lead the validation and development of novel therapies for the treatment of rare cancers.